1. Multidrug resistance proteins and folate supplementation: therapeutic implications for antifolates and other classes of drugs in cancer treatment

   • J. H. Hooijberg
   • N. A. de Vries
   • G. J. Peters

   Review 15 December 2005 Pages: 1 - 12

   

2. Bortezomib interactions with chemotherapy agents in acute leukemia in vitro

   • Terzah M. Horton
   • Anurhadha Gannavarapu
   • Stacey L. Berg

   Original Article 15 November 2005 Pages: 13 - 23

   

3. Elemene displays anti-cancer ability on laryngeal cancer cells in vitro and in vivo

   • Lei Tao
   • Liang Zhou
   • Min Yao

   Original Article 10 November 2005 Pages: 24 - 34

   

4. CHOP plus etoposide and gemcitabine (CHOP-EG) as front-line chemotherapy for patients with peripheral T cell lymphomas

   • Jong Gwang Kim
   • Sang Kyun Sohn
   • Chang-Hak Sohn

   Original Article 25 November 2005 Pages: 35 - 39

   

5. Chemoprotection effect of retroviral vector encoding multidrug resistance 1 gene to allow intensified chemotherapy in vivo

   • Chun-Bao Guo
   • Ying-Cun Li
   • Xian-Qing Jin

   Original Article 12 November 2005 Pages: 40 - 49

   

6. Human breast cell lines exhibit functional α₂-adrenoceptors

   • Stella Maris Vázquez
   • Alejandro Gustavo Mladovan
   • Isabel Alicia Lüthy

   Original Article 15 November 2005 Pages: 50 - 61

   

7. Anti-tumor drug candidate 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole induces single-strand breaks and DNA-protein cross-links in sensitive MCF-7 breast cancer cells

   • Eileen Brantley
   • Smitha Antony
   • Yves Pommier

   Original Article 06 December 2005 Pages: 62 - 72

   

8. Novel fluoro-substituted camptothecins: in vivo antitumor activity, reduced gastrointestinal toxicity and pharmacokinetic characterization

   • William C. Rose
   • Punit H. Marathe
   • Mansukh C. Wani

   Original Article 14 October 2005 Pages: 73 - 85

   

9. Pilot phase II study of weekly chemotherapy with paclitaxel and carboplatin for refractory or relapsed small-cell lung cancer

   • Kiyoshi Mori
   • Yukari Kamiyama
   • Tetsuro Kodama

   Original Article 31 January 2006 Pages: 86 - 90

   

10. p53 Status does not affect photodynamic cell killing induced by hypericin

    • H. B. Lee
    • A. S. H. Ho
    • S. H. Teo

    Original Article 07 October 2005 Pages: 91 - 98

    

11. Dibenzocyclooctadiene lingnans: a class of novel inhibitors of P-glycoprotein

    • Qiangrong Pan
    • Qinghua Lu
    • Xun Hu

    Original Article 18 October 2005 Pages: 99 - 106

    

12. Phase I clinical trial of the farnesyltransferase inhibitor BMS-214662 administered as a weekly 24 h continuous intravenous infusion in patients with advanced solid tumors

    • Joseph P. Eder Jr
    • David P. Ryan
    • Jeffrey G. Supko

    Original Article 13 December 2005 Pages: 107 - 116

    

13. Enforced expression of cytosolic 5′-nucleotidase I confers resistance to nucleoside analogues in vitro but systemic chemotherapy toxicity precludes in vivo selection

    • Tasha Gray
    • Erin L. Morrey
    • H. Trent Spencer

    Original Article 15 December 2005 Pages: 117 - 128

    

14. Combination vinorelbine and capecitabine for metastatic breast cancer using a non-body surface area dosing scheme

    • Anne F. Schott
    • James M. Rae
    • Laurence H. Baker

    Clinical Trial Report 08 November 2005 Pages: 129 - 135

    

15. 5-Fluorouracil dose escalation enabled with PN401 (triacetyluridine): toxicity reduction and increased antitumor activity in mice

    • Muhammad Wasif Saif
    • Reid von Borstel

    Clinical Trial Report 27 September 2005 Pages: 136 - 142